SIETES :: 92261 citas

Resultados de la búsqueda por USA REFINAR BÚSQUEDA

1.

Anónimo. Opioid prescriptions fell 10 percent last year, report says . DIA Daily 2018:13. [Ref.ID 102519]

2.

Joseph A. Panel recommends FDA approval of epilepsy drug derived from marijuana. DIA Daily 2018:1. [Ref.ID 102518]

3.

Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

4.

Anónimo. “Substantial evidence” supports experimental cannabis drug for treatment of rare forms of epilepsy, FDA staff report says. DIA Daily 2018:1. [Ref.ID 102514]

5.

Anónimo. Hallucinations and pimavanserin (NUPLAZID), a new kind of drug for psychosis. ISMP Quarter Watch 2018:6. [Ref.ID 102509]

6.

Tsujimoto T, Kajio H, Shapiro MF, Sugiyama T. Risk of all-cause mortality in diabetic patients taking ß-blockers. Mayo Clin Proc 2017;93:409-18. [Ref.ID 102505]

7.

Carey B, Gebeloff R. Many people taking antidepressants discover they cannot quit. N Y Times (Print) 2018:7 de abril. [Ref.ID 102504]

8.

Anónimo. Outbreak Alert: Potential life-threatening vitamin K-dependent antagonist coagulopathy associated with synthetic cannabinoids use. Centers for Disease Control and Prevention 2018:5 de abril. [Ref.ID 102503]

9.

Joseph A. In rare advisory, surgeon general urges public to carry overdose-reversal medication. STAT Daily Recap 2018:5. [Ref.ID 102500]

10.

Anónimo. Continued popularity of antipsychotic drug quetiapine highlights problems with off-label use. DIA Daily 2018:6. [Ref.ID 102498]

11.

Novoa A. Las estrategias comerciales de la industria farmacéutica, matan: el caso de los opioides en EE.UU. NoGracias 2018:1. [Ref.ID 102497]

12.

Feuerstein A. Alkermes stumbles as FDA refuses to review depression drug. STAT Daily Recap 2018:6. [Ref.ID 102496]

13.

Olfson M, Wall MM, Liu SM, Blanco C. Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry 2018;175:enero. [Ref.ID 102495]

14.

Wen H, Hockenberry JM. Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees . JAMA Intern Med 2018:2 de abril. [Ref.ID 102494]

15.

Bradford AC, Bradford WD, Abraham A, Bagwell Adams G. Association between US state medical cannabis laws and opioid prescribing in the Medicare Part D population. JAMA Intern Med 2018:2 de abril. [Ref.ID 102493]

16.

Hill KP, Saxon AJ. The role of cannabis legalization in the opioid crisis. JAMA Intern Med 2018:2 de abril. [Ref.ID 102492]

17.

Thayer K. Synthetic pot warning issued as number of users experiencing severe bleeding jumps to 32. Chicago Tribune 2018:1. [Ref.ID 102490]

18.

Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants — United States, 2015–2016. Morbidity and Mortality Weekly Report 2018;67:30 de marzo. [Ref.ID 102488]

19.

Domenech de Cellès M, Magpantay FMG, King AA, Rohani P. The impact of past vaccination coverage and immunity on pertussis resurgence. Sci Transl Med 2018;10:28 de marzo. [Ref.ID 102484]

20.

King LM, Sanchez GV, Bartoces M, Hicks A, Fleming-Dutra KE. Antibiotic Therapy Duration in US Adults With Sinusitis. JAMA Intern Med 2018:26 de marzo. [Ref.ID 102480]